Cargando…
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282260/ https://www.ncbi.nlm.nih.gov/pubmed/30534474 http://dx.doi.org/10.1186/s40164-018-0122-9 |
_version_ | 1783378952689025024 |
---|---|
author | Xu, Hanxiao Jiao, Ying Qin, Shuang Zhao, Weiheng Chu, Qian Wu, Kongming |
author_facet | Xu, Hanxiao Jiao, Ying Qin, Shuang Zhao, Weiheng Chu, Qian Wu, Kongming |
author_sort | Xu, Hanxiao |
collection | PubMed |
description | Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations. |
format | Online Article Text |
id | pubmed-6282260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62822602018-12-10 Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine Xu, Hanxiao Jiao, Ying Qin, Shuang Zhao, Weiheng Chu, Qian Wu, Kongming Exp Hematol Oncol Review Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations. BioMed Central 2018-12-05 /pmc/articles/PMC6282260/ /pubmed/30534474 http://dx.doi.org/10.1186/s40164-018-0122-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Xu, Hanxiao Jiao, Ying Qin, Shuang Zhao, Weiheng Chu, Qian Wu, Kongming Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title_full | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title_fullStr | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title_full_unstemmed | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title_short | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
title_sort | organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282260/ https://www.ncbi.nlm.nih.gov/pubmed/30534474 http://dx.doi.org/10.1186/s40164-018-0122-9 |
work_keys_str_mv | AT xuhanxiao organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine AT jiaoying organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine AT qinshuang organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine AT zhaoweiheng organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine AT chuqian organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine AT wukongming organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine |